Priya Saini

Priya Saini

Auto-generated profile, based on publicly available information

Priya Saini

IQVIA, Omega Block, Outer Ring Road, Embassy Tech Square, Bengaluru – 560103, Karnataka, India

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
7 March 2017 in Molecular Biotechnology
Verified
Journal Article
Closed access
PDF file
PSPriya Saini
Priya Saini
DSDipti Sareen
Dipti Sareen

1 December 2014 in Protein Expression and Purification
Verified
Journal Article
Closed access
PSPriya Saini
Priya Saini
SWShadil Ibrahim Wani
Shadil Ibrahim Wani
RKRanjai Kumar
Ranjai Kumar
RCRavneet Chhabra
Ravneet Chhabra
SCSwapandeep Singh Chimni
Swapandeep Singh Chimni
DSDipti Sareen
Dipti Sareen

15 September 2020 in The Applied Biology & Chemistry Journal
Verified
Journal Article
Open access
PSPriya Saini
Priya Saini
By the end of the year 2019, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) originated in China. With the passage of more than half of the year 2020, the virus has spread worldwide, making it the worst pandemic of our lifetime. The spread of the virus is controlled by imposing lockdown, which has led to severe economic slowdown around the globe. Coronaviruses are zoonotic as they spread from animals to humans. Factors such as rapid urbanization and poultry farming have permitted inter-mixing of species leading to crossing barriers and spreading of viruses to humans. Coronavirus disease (COVID-19) caused by SARS-CoV-2 is acute in most people, but it may progress to severe respiratory distress, especially in people with weak innate immunity leading to death. It is a contagious infection with the death toll mounting to above seven lakhs in the world, so there is an urgent need to find the vaccine to cure the virus, as there is no licensed drug or vaccine available. Global collaborations and increased research efforts among the scientific community have led to more than 150 clinical trials globally. This review discusses the SARS-CoV-2 replication mechanism and potential vaccine candidates in phase III COVID-19 clinical trials. Measures adopted to accomplish the fast pace of the COVID-19 trials are highlighted with an update on possible new drug targets or strategies to fight off the virus.

4 April 2017 in World Journal of Microbiology and Biotechnology
Verified
Journal Article
Closed access
PDF file
PSPriya Saini
Priya Saini
NKNaveen Kumar
Naveen Kumar
SWShadil Ibrahim Wani
Shadil Ibrahim Wani
SSShilpi Sharma
Shilpi Sharma
SCSwapandeep Singh Chimni
Swapandeep Singh Chimni
DSDipti Sareen
Dipti Sareen

6 February 2019
Verified
Book Chapter
Closed access
PDF file
PSPriya Saini
Priya Saini
DSDipti Sareen
Dipti Sareen